Zolbetuximab was evaluated as monotherapy in the third-line setting and in combination with chemotherapy (mFOLFOX6) in the first-line setting or with immunotherapy (pembrolizumab) in the third-line setting for advanced CLDN18.2-positive GC. This evidence concerns the gene CLDN18 and gastric cancer.